|
|
|
|
Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic HCV genotype 3 infection
|
|
|
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
C. HEZODE 1, V. LEROY 2, I. ROSA 3, F. ROUDOT-THORAVAL 1 , JM. PAWLOTSKY 4 , V. de LEDINGHEN 5 , and JP. BRONOWICKI 6
1 Hepatology, CHU Henri Mondor, Creteil, France; 2 Hepatology, CHU Michallon, Grenoble, France; 3 Hepatology, Hopital Intercommunal, Creteil, France
4 Virology, CHU Henri Mondor, Creteil, France; 5 Hepatology, CHU Haut Leveque, Bordeaux, France; 6 Hepatology, CHU de Brabois, Nancy, France
|
|
|
|
|
|
|